Objectives
The Nanoparticles Unit provides accredited tests and analyses for R&D on nanoparticles for therapeutic strategies.
Areas of impact and applications in the field
Theranostic nanoparticles hold the potential to revolutionize future disease management. Over the past ten years, there has been a growing interest in the engineering of various kinds of theranostic nanoparticles for simultaneous cancer imaging and therapy in small animals. Efficient targeting of theranostic nanoparticles to the tumor site is crucial for both diagnostic and therapeutic purposes. However, there are still difficulties in developing biocompatible theranostic nanoparticles with highly specific in vivo tumor targeting capabilities.
Areas of impact and applications in the field
Regarding cancer research, synthetic biology seeks to re-design biological systems to perform novel functions in a predictable way. Recent advances in bacterial and mammalian cell engineering include the development of cells that function in biological samples or within the body as minimally invasive diagnostics or theranostics for the real-time regulation of complex pathological conditions. Ex-vivo and in-vivo cell-based biosensors and therapeutics have been developed to target a wide range of diseases including cancer.
A major milestone in the field of theranostic cell engineering was the 2017 FDA approval of tisagenlecleucel, the first gene therapy to be approved in the USA. Considering the above, this facility will work on preclinical applications of mammalian sensing and drug delivery platforms as well as underlying biological designs that could lead to new classes of cell diagnostics and therapeutics.
In the context of infectious diseases, there is a growing need for novel, specific, sensitive, and effective diagnostic and treatment procedures. Synthetic systems and devices are evolving into strong tools for treating human infections. The advancement of synthetic biology provides platforms for detecting and preventing infectious diseases that are efficient, accurate, and cost-effective.